Handelsavisen
prelaunch
SR
SRXH.K NYSE Diversified Food Producers

Srx Health Solutions Inc

$0,17
Open in Charts → Attach watcher ⌖
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
95,1M USD
P/E
EV / Rev
11,8x
Div yield
Op margin
-31,2 %
ROE
-251,3 %
Net margin
-35,8 %
Debt / equity
4,64
Beta
52w range
Volume
90,9k
Day range
$0,11–$0,12
Prev close
$0,12
Open
$0,12
Next earnings
2026-10-28
Ex-dividend
TR 1Y
About

Srx Health Solutions Inc operates in the Food Processing industry, providing food-related products and services to consumers, primarily generating revenue through the sale of processed food items.

Business. Srx Health Solutions Inc (SRXH.K) is a food processing company operating within the Consumer Non-Cyclicals sector. The firm generates revenue through the sale of food products. Specific details regarding its operating segments and geographic presence are not available. The company is listed on the NYSE under the ticker symbol SRXH.K.

Classification99 %
SectorConsumer Staples
Industry groupDiversified Food Producers
Generated · model-assisted
Sell-side consensus
consensus pending
— buy— hold— sell
Avg 12m price target
Upcoming events
  • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
See all catalysts →

At a glance

Score
not yet scored
Valuation
valuation pending
Analysts
not yet wired
Ownership
Geode Capital Management, L.L.C.
largest disclosed fund holder
Profitability
-251,3 %
return on equity
Quality
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning SRXH.
  • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples · THIS SECTOR−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to SRXH.K. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Company
    • EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    Briefing · model-assisted

    Srx Health Solutions Inc (SRXH.K) has recorded its first analysis, establishing a baseline for future monitoring as no prior data exists for delta computation. This initial snapshot reveals a notable addition to the company's shareholder registry, marking a specific point of interest for investors tracking early-stage capital movements. The primary signal detected is a new holder addition as of June 30, 2024. An investor identified by ID 466 acquired a position of 56 shares, valued at approximately $0.000218 million. This transaction represents a weight of roughly 4.94e-09 percent of the total equity, indicating a micro-scale entry into the company's capital structure. Despite this new holder activity, the broader institutional landscape remains sparse. The company currently reports zero analyst coverage and zero index memberships, suggesting limited visibility in mainstream financial markets. Furthermore, the officer count is listed as zero, which may reflect data reporting limitations or the specific corporate structure at the time of this initial analysis. The significance of this development lies in the establishment of a foundational data point for SRXH.K. With six top holders now identified and the first holder change logged, the company has moved from an unanalyzed state to one with observable, albeit minimal, shareholder activity. This baseline allows for the tracking of future accumulation or distribution trends, though the current scale of investment remains negligible in terms of total market value. [doc:srxh.k-ha-financials]

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    Srx Health Solutions Inc (SRXH.K) is a food processing company operating within the Consumer Non-Cyclicals sector. The firm generates revenue through the sale of food products. Specific details regarding its operating segments and geographic presence are not available. The company is listed on the NYSE under the ticker symbol SRXH.K.

    Classification99 %
    SectorConsumer Staples
    Industry groupDiversified Food Producers
    AI synthesis
    GENERATED

    Srx Health Solutions Inc exhibits a capital structure with a high debt-to-equity ratio of 4.64, indicating a significant reliance on debt financing. The company's liquidity position is characterized by a current ratio of 1.02, suggesting limited short-term liquidity cushion. Despite holding $3.88 million in cash and equivalents, the company's long-term debt of $5.23 million and negative operating cash flow of $1.01 million raise concerns about its ability to meet long-term obligations.

    Profitability metrics reveal a challenging financial position. The company reported a net loss of $2.83 million and an operating loss of $2.47 million, with a return on equity of -2.51% and a return on assets of -0.18%. These figures fall significantly below the industry's median profitability metrics, indicating underperformance relative to peers.

    The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks and limits the ability to offset regional downturns.

    Growth trajectory is negative, with the company reporting a decline in operating cash flow and a net loss in the latest period. The absence of disclosed revenue growth or expansion plans suggests limited near-term upside potential.

    The company faces moderate liquidity risk due to its negative operating cash flow and high debt load. While dilution risk is currently low, the company's capital structure and financial performance could necessitate future equity issuance, potentially diluting existing shareholders.

    Recent filings and transcripts indicate ongoing financial challenges, with the company reporting a net loss and negative cash flow. No material strategic developments or operational improvements were disclosed in the latest available documents.

    Srx Health Solutions Inc (SRXH.K) has recorded its first analysis, establishing a baseline for future monitoring as no prior data exists for delta computation. This initial snapshot reveals a notable addition to the company's shareholder registry, marking a specific point of interest for investors tracking early-stage capital movements. The primary signal detected is a new holder addition as of June 30, 2024. An investor identified by ID 466 acquired a position of 56 shares, valued at approximately $0.000218 million. This transaction represents a weight of roughly 4.94e-09 percent of the total equity, indicating a micro-scale entry into the company's capital structure. Despite this new holder activity, the broader institutional landscape remains sparse. The company currently reports zero analyst coverage and zero index memberships, suggesting limited visibility in mainstream financial markets. Furthermore, the officer count is listed as zero, which may reflect data reporting limitations or the specific corporate structure at the time of this initial analysis. The significance of this development lies in the establishment of a foundational data point for SRXH.K. With six top holders now identified and the first holder change logged, the company has moved from an unanalyzed state to one with observable, albeit minimal, shareholder activity. This baseline allows for the tracking of future accumulation or distribution trends, though the current scale of investment remains negligible in terms of total market value. [doc:srxh.k-ha-financials]

    Key takeaways
    • Srx Health Solutions Inc is operating at a net loss with negative cash flow, indicating financial distress.
    • The company's high debt-to-equity ratio and low liquidity position raise concerns about its ability to meet obligations.
    • Lack of geographic and segment diversification increases exposure to market-specific risks.
    • The company's financial performance is significantly below industry medians, suggesting underperformance relative to peers.

    Bull / Bear case

    Generated · model-assisted
    BULL CASE · 5

    SRXH reduced long-term debt significantly from $11.4 million in 2023 to $2.4 million in 2025, improving its balance sheet.

    The company achieved a positive operating income of $239,000 in fiscal year 2025, marking a return to operational profitability.

    SRXH maintained a current ratio of 2.29 as of September 2025, indicating adequate short-term liquidity to cover liabilities.

    Dilution risk is assessed as low, suggesting limited immediate threat to existing shareholder equity value from share issuance.

    Capital expenditure relative to revenue was above the 75th percentile of the Food Processing cohort, indicating efficient capital usage.

    BEAR CASE · 4

    The company reported a massive net loss of $45.1 million in the latest period, drastically worsening profitability metrics.

    SRXH faces high credit risk and carries a high leverage band with a debt-to-equity ratio of 19.64.

    Operating and net margins are in the bottom quartile of the Food Processing cohort, indicating poor competitive positioning.

    Free cash flow deteriorated sharply to a negative $8.6 million, highlighting significant cash burn and liquidity pressure.

    In focus — financials by report

    Annual
    ANNUALFiled 2025-03-27
    FY 2025 · Full-year highlights

    Revenue $35.0M, −9,4% YoY; Operating income +101,1% YoY.

    Revenue$35.0M−9,4 % YoY
    Operating income$239.0k+101,1 % YoY
    Net income-$168.0k+99,3 % YoY
    Free cash flow-$79.0k+99,6 % YoY
    EPS
    Operating cash flow-$4.4M−4 591,8 % YoY
    Financials
    Income statement
    Revenue$35.0M
    Gross profit$13.0M
    Operating income$239.0k
    Net income-$168.0k
    Margins
    Gross margin37.1%
    Operating margin0.7%
    Net margin-0.5%
    FCF margin-0.2%
    Balance sheet
    Total assets$15.8M
    Total liabilities$7.2M
    Total equity$8.6M
    Cash & equivalents$3.1M
    Long-term debt$2.4M
    Cash flow
    Operating cash flow-$4.4M
    CapEx-$41.0k
    Free cash flow-$79.0k
    SBC
    P&L flow · revenue → net income
    Revenue $7.9MOperating costs $10.4MFinance $362.0kNet income $2.8M
    Highlights
    • Revenue $35.0M, −9,4% YoY
    • Operating income +101,1% YoY
    • Net income +99,3% YoY
    • Free cash flow +99,6% YoY
    • Net margin -0.5%

    Valuation FY

    Market price
    $0,17
    Market cap
    $76.0M
    Enterprise value
    $77.3M
    P/E
    Non-GAAP P/E
    EV / Revenue
    11.8x
    EV / Op income
    EV / OCF
    P / B
    67.5x
    P / Tangible book
    67.5x
    Tangible book
    $1.1M
    Net cash
    -$1.3M
    Current ratio
    1.0
    Debt / equity
    4.6
    ROA
    -18.3%
    ROE
    -2.5%
    Cash conversion
    36.0%
    CapEx / revenue
    -0.0%
    SBC / revenue
    Dilution ratio
    0.0%

    Revenue by segment

    Pet Dental Care
    low · business_description · 2026-07-03
    Pet Food & Nutrition
    low · business_description · 2026-07-03
    Pet Supplements & Treats
    low · business_description · 2026-07-03

    Market share

    INDUSTRYSEGMENTCOMPANYConsumer Non-CyclicalsIndustryDiversified Food Producers468,7B node revenueJBS 18,4%TSN 11,6%MDLZ 8,2%ADM 5,3%KHC 5,3%BIP 4,9%GIS 4,2%PPC 4,0%Other 38,1%
    Source: company disclosures · own-taxonomy revenue-covered setSRXH 0,0% · rank #55 of 65

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    Peer comparison8 peers · vs SRXH · multiples and returns
    JB
    JBS
    JBS
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    TS
    TSN
    Tyson Foods Inc
    $59,61
    21,1B USD
    P/E
    45,3x
    vs self
    Div yield
    vs self
    ROE
    2,6 %
    +254,0 vs self
    MD
    MDLZ
    MONDELEZ INTERNATIONAL, INC.
    $61,73
    80,1B USD
    P/E
    28,9x
    vs self
    Div yield
    3,3 %
    vs self
    ROE
    10,1 %
    +261,4 vs self
    AD
    ADM
    Archer-daniels-midland Co
    $78,06
    37,8B USD
    P/E
    36,8x
    vs self
    Div yield
    2,5 %
    vs self
    ROE
    4,7 %
    +256,1 vs self
    KH
    KHC
    THE KRAFT HEINZ COMPANY
    $26,44
    31,3B USD
    P/E
    vs self
    Div yield
    6,5 %
    vs self
    ROE
    -13,8 %
    +237,5 vs self
    BI
    BIP
    BIP.WA
    P/E
    vs self
    Div yield
    vs self
    ROE
    vs self
    GI
    GIS
    General Mills Inc
    $36,08
    19,4B USD
    P/E
    vs self
    Div yield
    6,6 %
    vs self
    ROE
    -1,2 %
    +250,1 vs self
    PP
    PPC
    PILGRIM'S PRIDE LTD.
    $27,92
    6,6B USD
    P/E
    6,4x
    vs self
    Div yield
    vs self
    ROE
    29,4 %
    +280,7 vs self

    Market position

    Stress test

    — missing data

    Predictor forecast

    Corporate eventM&A horizon
    M&A probabilityconf 5 %
    Probability
    5 %
    Base rate
    3 %
    Band
    180-day horizon · target 2027-01-16 · 1,8× base rate
    No acquirer candidates identified by the signal model.
    Probabilistic model output — not investment advice. · generated 2026-07-20

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskMedium
    Filing-based flags
    • Net cash is negative after subtracting total debt.

    Benchmarks vs cohort

    Op Margin-31,2 %Bottom quartile
    Net Margin-35,8 %Bottom quartile
    ROE-251,3 %Bottom quartile
    Capex / Rev-0,0 %Above median
    D/E4,64Bottom quartile
    Cash Conv0,36Below median

    Corporate actions / M&A

    M&A probabilityconf —
    Probability
    5 %
    Base rate
    3 %
    Band
    Moderate
    180-day horizon · target 2027-01-16 · 1,8× base rate
    No acquirer candidates identified by the signal model.
    Corporate actionsNo corporate-action source connected yet — splits, dividends and buyback events are not tracked for this company. Honest-dim (no data fabricated).

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    Derivative transactions

    Net acquired 247 522 sh1 grants1 insiders
    • Cunningham Kent DouglasChief Executive Officer · Series B Warrants → Common StockAcquired 247 522 @ $0,32grant · 2026-03-16

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Return On Equity
      net_income / total_equity
    • Price To Book
      market_price / (adjusted_book_value / shares_outstanding_diluted)
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Market Price
      input from market-data provider (delayed close or quote-shim mid)
    • Market Cap
      market_price * shares_outstanding_diluted
    • Ev To Revenue
      enterprise_value / revenue
    Source documents
    • Srx Health Solutions Inc Market data — financials · 2026-05-29

    Ownership & reference

    Top holders

    • Geode Capital Management, L.L.C.Investment Managers · as of 2026-03-310,00 %$0M
    • UBS Financial Services, Inc.Investment Managers · as of 2026-03-310,00 %$0M
    • Vanguard Capital Management, LLCInvestment Managers · as of 2025-12-310,00 %$0M
    • Fisher InvestmentsInvestment Managers · as of 2026-03-310,00 %$0M
    • Morgan Stanley Smith Barney LLCInvestment Managers · as of 2026-03-310,00 %$0M
    • BlackRock Institutional Trust Company, N.A.Investment Managers · as of 2024-06-300,00 %$0M

    Insider activity

    Mixed / flat0 buys · 0 sellsnet $03 insiders · last 365d
    • Cunningham Kent DouglasChief Executive Officer · Series B Preferred StockOther 63 @ $800,00$50K · 2026-03-16
    • Conway Simon Alexander MalcolmDirector · Common StockOther 630 000 @ $0,39$246K · 2025-12-03
    • Cunningham Kent DouglasChief Executive Officer · Common StockOther 200 000 @ $0,39$78K · 2025-12-03
    • Cunningham Kent DouglasChief Executive Officer · Common StockOther 44 464 @ $0,33$15K · 2025-09-26
    • White David AllanDirector · Common StockOther 154 128 @ $0,40$62K · 2025-08-25
    • Cunningham Kent DouglasChief Executive Officer · Common StockOther 231 193 @ $0,40$93K · 2025-08-25
    • Conway Simon Alexander MalcolmDirector · Common StockOther 154 128 @ $0,40$62K · 2025-08-25

    Short positioning

    2.7Mshares short-88.5% vs prior
    1days to cover
    45.8%short of daily vol
    214.8Kfails-to-deliver
    as of 2026-07-15 · short-interest report (free)

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    SRXH.KCanonical
    NYSE · USD

    Intel & risk

    PredictorM&A prob5 %Full forecast →
    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskMedium
    Net cash is negative after subtracting total debt.

    Evidence & claims

    From filings & derived data
    • Total liabilities (YoY) (2025-12-31 vs 2024-12-31): 228.9%Derived (calculated)
    • Current ratio (FY 2025-12-31): 0.80xDerived (calculated)
    • Total assets (YoY) (2025-12-31 vs 2024-12-31): 71.2%Derived (calculated)
    • Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 105.5%Derived (calculated)
    • Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): 326.0%Derived (calculated)
    • Debt-to-equity (FY 2025-12-31): 6.68xDerived (calculated)
    • Total liabilities (annual): USD 23.53MSEC XBRL filing
    • Total assets (annual): USD 27.05MSEC XBRL filing
    • Current liabilities (annual): USD 23.53MSEC XBRL filing
    • Shareholders' equity (annual): USD 3.52MSEC XBRL filing
    • Cash & equivalents (annual): USD 13.06MSEC XBRL filing
    • Shares outstanding (annual): 98.76MSEC XBRL filing
    • Current assets (annual): USD 18.84MSEC XBRL filing
    • Gross margin (FY 2025-09-30): 23.4%Derived (calculated)
    • Cost of revenue (YoY) (2025-09-30 vs 2024-12-31): -77.2%Derived (calculated)
    • EPS (basic) (YoY) (2025-09-30 vs 2024-12-31): -2,030.0%Derived (calculated)
    • Revenue (YoY) (2025-09-30 vs 2024-12-31): -81.3%Derived (calculated)
    • Operating income (YoY) (2025-09-30 vs 2024-12-31): -91.2%Derived (calculated)
    • Operating cash flow (YoY) (2025-09-30 vs 2024-12-31): -86.9%Derived (calculated)
    • Net income (YoY) (2025-09-30 vs 2024-12-31): -26,689.3%Derived (calculated)
    • Gross profit (YoY) (2025-09-30 vs 2024-12-31): -88.3%Derived (calculated)
    • Net margin (FY 2025-09-30): -688.8%Derived (calculated)
    • EPS (diluted) (YoY) (2025-09-30 vs 2024-12-31): -2,030.0%Derived (calculated)
    • EPS (diluted) (annual): USD-PER-SHARES -2SEC XBRL filing
    Showing 24 of 60 surfaced claims.
    Atomic claims from regulatory filings and derived calculations. Provenance shown as source kind only.

    The Thread

    Everything we know, in order
    2026-10-28EVENTUpcomingQ3 2026 earnings (expected) estimated date
    2026-06-30 03:38 UTCEARNINGSUpcomingForecast: ma_probability (180d)
    2026-06-21 02:57 UTCHOLDERInstitutional holding changed
    2026-06-21 02:57 UTCHOLDER1 institutional position change flagged
    2026-06-18FILING8-K filing →
    2026-06-08FILING424B3 filing →
    2026-06-08FILING424B3 filing →
    2026-05-14FILING10-Q filing →
    2026-05-07FILING424B3 filing →
    2026-04-22FILING8-K filing →
    2026-04-17FILING8-K filing →
    2026-03-18FILING8-K filing →
    2026-03-16 00:00 UTCINSIDER2 insider transactions — 2026-03 1 derivative
    2026-03-16 00:00 UTCINSIDER2 insider transactions — 2026-03 1 derivative
    2026-03-16INSIDERCunningham Kent Douglas transacted 63 sh Series B Preferred Stock — Chief Executive Officer ~$50k
    2026-03-16INSIDERCunningham Kent Douglas acquired 247.5k sh Series B Warrants — Chief Executive Officer
    2026-03-06FILING424B3 filing →
    2026-03-06FILING424B3 filing →
    2026-03-03FILING8-K filing →
    2026-02-27FILING424B3 filing →
    2025-12-03 00:00 UTCINSIDER2 insider transactions — 2025-12 · net buy $324k
    2025-12-03 00:00 UTCINSIDER2 insider transactions — 2025-12 · net buy $324k
    2025-12-03INSIDERConway Simon Alexander Malcolm transacted 630.0k sh — Director ~$246k
    2025-12-03INSIDERCunningham Kent Douglas transacted 200.0k sh — Chief Executive Officer ~$78k
    2025-09-26 00:00 UTCINSIDER1 insider transaction — 2025-09
    2025-09-26 00:00 UTCINSIDER1 insider transaction — 2025-09
    2025-09-26INSIDERCunningham Kent Douglas transacted 44.5k sh — Chief Executive Officer ~$15k
    2025-08-25 00:00 UTCINSIDER3 insider transactions — 2025-08 · net buy $217k
    2025-08-25 00:00 UTCINSIDER3 insider transactions — 2025-08 · net buy $217k
    2025-08-25INSIDERWhite David Allan transacted 154.1k sh — Director ~$62k
    2025-08-25INSIDERCunningham Kent Douglas transacted 231.2k sh — Chief Executive Officer ~$93k
    2025-08-25INSIDERConway Simon Alexander Malcolm transacted 154.1k sh — Director ~$62k
    2025-03-27 16:05 UTCEARNINGSAnnual results — FY 2025 Revenue USD 35.0M · Net USD -0.2M
    2024-04-12 15:00 UTCEARNINGSAnnual results — FY 2024 Revenue USD 38.6M · Net USD -22.8M
    2023-03-28 07:00 UTCEARNINGSAnnual results — FY 2023 Revenue USD 54.7M · Net USD -39.3M
    2022-03-29 07:26 UTCEARNINGSAnnual results — FY 2022 Revenue USD 46.0M · Net USD 3.4M
    The entity's full life in the product — typed, chronological, joined across Newspaper, Platform and Data. Our memory, made visible.
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage